<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02664207</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-15-0795</org_study_id>
    <nct_id>NCT02664207</nct_id>
  </id_info>
  <brief_title>Extended Criteria For Fetal Myelomeningocele Repair</brief_title>
  <official_title>Extended Criteria For Fetal Myelomeningocele Repair: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to offer pre-natal Myelomeningocele (MMC) repair surgery to&#xD;
      pregnant women with one of the former surgery exclusion factors&#xD;
&#xD;
        -  A BMI of 35-40 kg/m2&#xD;
&#xD;
        -  Diabetes; patients will require good glycemic control&#xD;
&#xD;
        -  History a previous preterm birth, as long as it was followed by a full term birth&#xD;
&#xD;
        -  Structural abnormality in the fetus; abnormality must be minor, not increasing the risk&#xD;
           of prematurity. For example cleft lip and palate, minor ventricular septal defect,&#xD;
           pyelectasis.&#xD;
&#xD;
        -  Maternal Rh alloimmunization. Must have a low level of anti-red blood cell antibody that&#xD;
           is not associated with fetal disease, specifically anti-E &lt; 1:4 or anti-M. Or&#xD;
           alloimmunization with negative fetal red blood cell antigen status determined by&#xD;
           amniocentesis.&#xD;
&#xD;
      We will be extending the Management of Myelomeningocele Study (MOMs) criteria by including&#xD;
      these factors. Prenatal clinical and outcome information will be collected; safety and&#xD;
      efficacy will be evaluated&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to extend the MOMs requirements for pre-natal MMC repair surgery&#xD;
      and evaluate safety and efficacy. This will be accomplished through prenatal and&#xD;
      post-operative observation and data collection.&#xD;
&#xD;
      The data collected will be documented and collected from prenatal ultrasounds, operative, and&#xD;
      delivery reports. We will share our preliminary data with NAFTNet in order to prompt a&#xD;
      multicenter trial; this collaboration will help propagate further research and answer&#xD;
      clinical questions regarding this extension in surgery criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 26, 2016</start_date>
  <completion_date type="Anticipated">January 2028</completion_date>
  <primary_completion_date type="Anticipated">January 2028</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative complications</measure>
    <time_frame>At the time of fetal repair surgery to 40 weeks gestation</time_frame>
    <description>Determine if there is an increased risk in women in this group</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Obesity</condition>
  <condition>Myelomeningocele</condition>
  <condition>Pregnancy</condition>
  <condition>Diabetes Mellitus in Pregnancy</condition>
  <condition>Fetal Anomaly</condition>
  <arm_group>
    <arm_group_label>Fetal Surgery in Women with ex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fetal myelomeningocele repair surgery will be offered to pregnant women meeting the criteria for surgery (as set by the MOMS trial) with the exception of the following:&#xD;
a BMI greater than 35 (but less than or equal to 40 kg/m2)&#xD;
(minor) Fetal structural abnormality&#xD;
(well-controlled) Diabetes&#xD;
Previous preterm delivery (followed by a full term delivery)&#xD;
Maternal red cell alloimmunization (must NOT be associated with fetal disease, OR fetus must have negative red cell antigen status as determined by amniocentesis).&#xD;
Intervention: Open Fetal Repair of Myelomeningocele</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Open Fetal Repair of Myelomeningocele</intervention_name>
    <description>Fetal repair of myelomeningocele in women with additional medical factors that would have excluded them from this treatment under the MOMs trial inclusion/exclusion criteria</description>
    <arm_group_label>Fetal Surgery in Women with ex</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any woman with a prenatal diagnoses of myelomeningocele.&#xD;
&#xD;
          -  Pre-pregnancy BMI of 35-40 kg/m2.&#xD;
&#xD;
          -  Diabetes; patients will require good glycemic control&#xD;
&#xD;
          -  History a previous preterm birth, as long as it was followed by a full term birth&#xD;
&#xD;
          -  Structural abnormality in the fetus; abnormality must be minor, not increasing the&#xD;
             risk of prematurity. For example cleft lip and palate, minor ventricular septal&#xD;
             defect, pyelectasis.&#xD;
&#xD;
          -  Maternal Rh alloimmunization. Must have a low level of anti-red blood cell antibody&#xD;
             that is not associated with fetal disease, specifically anti-E &lt; 1:4 or anti-M. Or&#xD;
             alloimmunization with negative fetal red blood cell antigen status determined by&#xD;
             amniocentesis.&#xD;
&#xD;
          -  same MOMs Trial inclusion criteria with the exception of the above.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  poor glycemic control (i.e., HbA1c â‰¥ 8%) in spite a medical antidiabetic therapy in&#xD;
             accordance with good clinical practice (GCP)&#xD;
&#xD;
          -  presence of significant co-morbidities or complications (such as dyslipidemia,&#xD;
             uncontrolled arterial hypertension, impaired renal function, neuropathy, retinopathy,&#xD;
             CVD)&#xD;
&#xD;
          -  severe diabetes complications or associated medical conditions (such as blindness,&#xD;
             endstage renal failure, liver cirrhosis, malignancy, chronic congestive heart failure)&#xD;
&#xD;
          -  recent (within preceding 12 months) myocardial infarction, stroke or TIA&#xD;
&#xD;
          -  unstable angina pectoris&#xD;
&#xD;
          -  same MOMs Trial exclusion criteria (with the exception of extended inclusion criteria)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kuojen Tsao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center at Houston - UTHealth.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kuojen Tsao, MD</last_name>
    <phone>713-500-7327</phone>
    <email>KuoJen.Tsao@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yisel Morales, B.S.</last_name>
    <phone>713-486-6560</phone>
    <email>yisel.morales@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Memorial Hermann Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kuojen Tsao, MD</last_name>
      <phone>713-500-7327</phone>
      <email>KuoJen.Tsao@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Meagan Sosa, M.A.</last_name>
      <phone>713-486-6573</phone>
      <email>Meagan.D.Sosa@uth.tmc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Fetal Center at UTHealth</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kuojen Tsao, MD</last_name>
      <phone>713-500-7327</phone>
      <email>KuoJen.Tsao@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Meagan Sosa, M.A.</last_name>
      <phone>713-486-6573</phone>
      <email>Meagan.D.Sosa@uth.tmc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://childrens.memorialhermann.org/the-fetal-center/</url>
    <description>The Fetal Center at Children's Memorial Hermann Hospital</description>
  </link>
  <reference>
    <citation>Adzick NS, Thom EA, Spong CY, Brock JW 3rd, Burrows PK, Johnson MP, Howell LJ, Farrell JA, Dabrowiak ME, Sutton LN, Gupta N, Tulipan NB, D'Alton ME, Farmer DL; MOMS Investigators. A randomized trial of prenatal versus postnatal repair of myelomeningocele. N Engl J Med. 2011 Mar 17;364(11):993-1004. doi: 10.1056/NEJMoa1014379. Epub 2011 Feb 9.</citation>
    <PMID>21306277</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 19, 2016</study_first_submitted>
  <study_first_submitted_qc>January 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2016</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>KuoJen Tsao</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Myelomeningocele repair</keyword>
  <keyword>Open Neural Tube Defect</keyword>
  <keyword>BMI of 35-40 kg/m2,</keyword>
  <keyword>Open Fetal Surgery</keyword>
  <keyword>Elevated body mass index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningomyelocele</mesh_term>
    <mesh_term>Spina Bifida Cystica</mesh_term>
    <mesh_term>Pregnancy in Diabetics</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

